Revolution Medicines Q4 FY25 earnings call RVMD

Revolution Medicines is advancing a robust pipeline of four novel investigational RAS(ON) inhibitors: daraxonrasib (multi-selective), elironrasib (G12C selective), zoldonrasib (G12D selective), and RMC-5127 (G12V selective). These compounds target major oncogenic RAS drivers, with over 2,500 patients having received one or more of these inhibitors in clinical trials to date. The company emphasizes its leadership in RAS targeting with a strong discovery and preclinical platform.

The company's most advanced clinical program is in pancreatic cancer, where over 90% of cases are RAS-driven. Daraxonrasib is being evaluated in three randomized registrational studies: RASolute 302 (second-line metastatic, global enrollment complete, readout H1 2026), RASolute 303 (first-line metastatic, initiated), and RASolute 304 (adjuvant setting, initiated). Daraxonrasib received FDA Breakthrough Therapy Designation and a Commissioner's National Priority Voucher for pancreatic cancer.

Zoldonrasib, a covalent G12D selective inhibitor, showed encouraging initial data in first-line metastatic pancreatic cancer when combined with FOLFIRINOX, achieving a 63% partial response rate and 95% disease control rate. This led to the initiation of RASolute 305, a randomized trial evaluating zoldonrasib with chemotherapy, and the planned initiation of RASolute 309 in H2 2026, which will evaluate a zoldonrasib plus daraxonrasib doublet combination.

NSCLC, with approximately 30% of cases harboring RAS mutations, remains a key priority. RASolve 301, a global randomized trial of daraxonrasib monotherapy in previously treated patients, is expected to substantially complete enrollment in 2026. The company plans to disclose its strategy for daraxonrasib combination therapy in first-line NSCLC this year. Zoldonrasib (G12D) and elironrasib (G12C) have also shown promising activity, with RASolve 308 (zoldonrasib in 1L G12D NSCLC) preparing for initiation.

Colorectal cancer, affecting about 50% of patients with a RAS mutation, is an area of high interest. Due to its genetic complexity, the company is focusing on combinatorial approaches, including RAS(ON) inhibitor doublets and combinations with current standards of care. The goal is to prioritize registrational opportunities, with plans to provide visibility into combination data in CRC this year.

Revolution Medicines' discovery team is pioneering a new class of RAS(ON) inhibitors designed to overcome RAS-driven drug resistance. Preclinical data with a representative compound, RM-055, demonstrated deep and durable regressions in models resistant to daraxonrasib. The company plans to share more information at a scientific meeting and initiate clinical development of the first compound from this class in H2 2026, marking its fifth clinical-stage RAS(ON) inhibitor.

As late-stage programs advance, Revolution Medicines is building a global oncology enterprise for potential commercialization, initially focused on the U.S. market. Key strategic hires have been made, and recruitment for the first field sales team is underway, indicating strong progress towards launch readiness.